Which hematologic malignancies are associated with erythrocytosis, elevated hematocrit, and increased hemoglobin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Polycythemia Vera is the Primary Blood Malignancy Associated with Elevated RBC, Hematocrit, and Hemoglobin

Polycythemia vera (PV) is the principal hematologic malignancy characterized by erythrocytosis (elevated hemoglobin >16.5 g/dL in men, >16.0 g/dL in women, or hematocrit >49% in men, >48% in women). 1 This is a JAK2-driven myeloproliferative neoplasm that affects approximately 65,000 people in the US with an annual incidence of 0.5-4.0 cases per 100,000 persons. 2

Diagnostic Criteria for Polycythemia Vera

According to the 2016 WHO criteria endorsed by the European LeukemiaNet, PV diagnosis requires:

Major Criteria:

  • Elevated hemoglobin (>16.5 g/dL men, >16.0 g/dL women) or hematocrit (>49% men, >48% women) 1
  • Bone marrow biopsy showing age-adjusted hypercellularity with trilineage myeloproliferation 1
  • Presence of JAK2 mutation (found in >95% of PV cases) 1, 2

Minor Criterion:

  • Subnormal serum erythropoietin level 1

Diagnosis requires either all three major criteria OR the first two major criteria plus the minor criterion. 1

Other Myeloproliferative Neoplasms with Potential Erythrocytosis

While PV is the primary malignancy, two other Philadelphia chromosome-negative myeloproliferative neoplasms can occasionally present with elevated blood counts:

Essential Thrombocythemia (ET)

  • Primarily presents with thrombocytosis (≥450 × 10⁹/L), not erythrocytosis 1
  • JAK2, CALR, or MPL mutations present in 50% of cases 1
  • Does NOT meet criteria for elevated hemoglobin/hematocrit that defines PV

Primary Myelofibrosis (PMF)

  • Typically presents with anemia, NOT erythrocytosis 1
  • Characterized by bone marrow fibrosis and megakaryocyte proliferation
  • JAK2, CALR, or MPL mutations present in approximately 50% of cases 1

Critical Distinguishing Features

The JAK2V617F mutation is the key molecular marker: It is present in >95% of PV cases but only ~50% of ET and PMF cases. 1, 2 This mutation, combined with erythrocytosis, essentially confirms PV rather than other myeloproliferative neoplasms.

Erythropoietin levels differentiate primary from secondary causes: PV shows subnormal erythropoietin levels, while secondary erythrocytosis (from hypoxia, sleep apnea, smoking, testosterone use) shows normal or elevated levels. 3, 4

Clinical Significance and Complications

PV carries significant morbidity and mortality risks:

  • Thrombotic events: 16% arterial thrombosis and 7% venous thrombosis at or before diagnosis 2
  • Transformation risk: 12.7% develop myelofibrosis and 6.8% develop acute myeloid leukemia 2
  • Median survival: 14.1 to 27.6 years from diagnosis 2

Common Pitfall to Avoid

Do not confuse relative polycythemia (plasma volume contraction) or secondary erythrocytosis with malignancy. 5 The presence of isolated erythrocytosis without leukocytosis or thrombocytosis should prompt investigation for secondary causes (hypoxia, sleep apnea, smoking, erythropoietin-secreting tumors, SGLT2 inhibitors, androgens) before assuming malignancy. 6, 5 However, when erythrocytosis occurs with leukocytosis (49% of PV cases) or thrombocytosis (53% of PV cases), immediately test for JAK2 mutations and serum erythropoietin levels. 2, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.